![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Author: He Yan-Ling
Publisher: Adis International
ISSN: 0312-5963
Source: Clinical Pharmacokinetics, Vol.46, Iss.7, 2007-01, pp. : 577-588
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Clinical Drug Investigation, Vol. 31, Iss. 9, 2011-09 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Vildagliptin improves -cell function in previously untreated patients with type 2 diabetes mellitus
Inpharma, Vol. 1, Iss. 1505, 2005-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Vildagliptin: A Review of its Use in Type 2 Diabetes Mellitus
Drugs, Vol. 70, Iss. 16, 2010-11 ,pp. :